ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1265

Impaired Cardiac Function in Juvenile Mixed Connective Tissue Disease Compared with Controls

Birgit Nomeland Witczak1, Siri Opsahl Hetlevik2, Zoltan Barth1,3, Thomas Schwartz4,5, Berit Flatø2,6, Vibke Lilleby2,6 and Ivar Sjaastad1,6,7, 1Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 3Department of Pathophysiology and Gerontology, Medical School, University of Pècs, Pècs, Hungary, Pècs, Hungary, 4Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, 5Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, 7Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, Disease Activity, Lipids, mixed connective tissue disease (MCTD) and ribonucleoprotein (RNP)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile MCTD (JMCTD) is a heterogenic autoimmune disease, with SLE-, SSc- and PM/DM and RA like manifestations. Cardiac involvement is known in juvenile SLE, SSc, JDM and JIA, but data is limited in JMCTD. Adult MCTD is more benign than other CTDs, and cardiac involvement is mainly subclinical. Mortality, however, is mostly related to cardiac causes. Aim of study was to compare cardiac function in JMCTD patients with controls, and explore associations between cardiac function and disease characteristics.

Methods: 50 patients and 50 matched controls were examined median 14.9 years after disease onset. Cardiac function was assessed by echocardiography; LV systolic function was assessed by biplane ejection fraction (EF) and normalized mitral annulus displacement (long axis strain (LAS)); LV diastolic function was assessed by early diastolic tissue velocity (E’), early diastolic transmitral flow (MV E), and early/ late diastolic transmitral flow ratio (MV E/A ratio). LV dysfunction was defined as EF≤61.6%, LAS≤15.3%, or E’≤9.3m/s, all defined by mean values -2 standard deviations in controls. Disease activity was assessed by SLEDAI, Juvenile Arthritis Disease Activity Score (JADAS), anti-RNP-levels and positive rheumatoid factor (RF). Patients were classified with SLE-like, SSc-like or PM-like findings.

Results: Table 1 shows characteristics and cardiovascular parameters in patients and controls. 86% were female; Mean age in patients was 27.4 years.

EF and LAS were lower in patients than controls (P≤0.001 and P=0.045), but within normal range. MV E and MV E/A ratio were also impaired in patients (P ≤0.029). LV dysfunction was present in 16% patients versus 4% controls (P=0.046).

At follow-up, JADA was associated with lower EF (rsp= -0.283, p0.049); Positive RF and higher SLEDAI at follow-up were associated with higher LAS (rsp=0.318, P=0.026 and rsp=0.281, P=0.048). Long duration of prednisolone treatment was associated with EF≤61.6% (rsp=0.340, P=0.016). 

In final multivariable regression models (table 2), PM-like findings at diagnosis was an independent predictor of impaired EF (P=0.001), male sex was independent predictor of impaired LAS (P=0.002), and long disease duration was independent predictor of impaired E’ (P≤0.001).

Conclusion: LV cardiac function was impaired in JMCTD patients compared with controls. Subclinical LV dysfunction was present in 16% of the patients. PM-like manifestation at diagnosis, male sex and long disease duration predicted impaired cardiac function. Our results suggest that cardiac involvement in JMCTD varies among the different clinical phenotypes.

Table 1. Characteristics and cardiovascular parameters in JMCTD patients and controls

JMCTD Patients

n=50

Controls

n=50

P-value

Female sex

43 (86%)

43 (86%)

NA

Variables assessed at diagnosis

SLE-like findings (n=49)

46 (94%)

NA

NA

SSc-like findings (n=49)

12 (25%)

NA

NA

PM-like findings (n=49)

15 (31%)

NA

NA

Anti-RNP, U/L (n=48)

240 (240-999)

NA

NA

Positive RF (n=42)

26 (62%)

NA

NA

Variables assessed at follow-up

Disease duration, years

14.9 (6.6-23.0)

NA

NA

Age, years

27.4 (9.9)

28.5 (9.9)

<0.001

Height, cm (n=49 pairs)

166.0 (7.5)

169.6 (8.6)

0.022

BMI, kg/m2 (n=49pairs)

22.8 (3.5)

23.5 (3.0)

0.279

SBP, mmHg (n=47pairs)

111.9 (14.5)

114.8 (11.9)

0.233

DBP, mmHg (n=47pairs)

64.8 (15.0)

67.9 (8.6)

0.177

Total duration of prednisolone (months)

12 (2-40)

NA

NA

SLE-like findings

27 (54%)

NA

NA

SSc-like findings

34 (68%)

NA

NA

PM-like findings

2 (4%)

NA

NA

Disease activity measures at follow-up

CRP, mg/L (n=41pairs)

0.70 (0.50-1.90)

0.60 (0.50-0.90)

0.108

ESR, mm (n=47pairs)

8.5 (5.0-16.0)

4.0 (2.0-7.0)

<0.001

Anti-RNP, U/L (n=49)

199 (38-240)

NA

NA

Positive RF (n=49)

17 (35%)

NA

NA

SLEDAI

0 (0-0)

NA

NA

JADA (n=49)

0 (0-0)

NA

NA

Echocardiography data at follow-up

LV ejection fraction, EF,  %

65.8 (4.5)

69.6 (4.0)

<0.001

LV length, mm

77.4 (7.2)

79.6 (6.3)

0.109

MA displacement, mm

MV medial, mm

13.7 (1.9)

14.3 (1.5)

0.094

MV lateral, mm

15.1 (1.7)

16.5 (2.0)

0.001

Long Axis Strain% (LAS%)

18.68 (1.94)

19.40 (2.07)

0.044

MV E velocity,  m/s

0.82 (0.12)

0.90 (0.16)

0.015

MV E/A ratio

1.95 (0.46)

2.16 (0.56)

0.029

E’ (cm/s)

12.38 (1.63)

12.86 (1.79)

0.129

Values are mean (SD) or median (IQR) or number (%). Anti-RNP, anti-ribonuceloprotein antibodies; BMI, body mass index;  CRP, c-reactive protein; DBP, diastolic blood pressure; E’, early diastolic tissue velocity; ESR, erythrocyte sedimentation rate;  JADA, Juvenile Arthritis Disease Activity Score; LA, left atrium;  LAS, long axis strain; LV, left ventricular; MA, mitral annulus; MV A, late diastolic transmitral flow; MV E, early diastolic transmitral flow; NA, not applicable; RF, rheumatoid factor; SBP, systolic blood pressure; SLEDAI, systemic lupus erythematosus disease activity index, SLICC, Systemic Lupus International  Collaborating Clinics/ACR Damage Index; n=50 pairs or 50 patients or 50 controls unless otherwise stated.

Table 2. Uni-and multivariable linear regression for predictors of cardiac left ventricular function in JMCTD at follow up.

UNIVARIABLE LINEAR REGRESSION

MULTIVARIABLE LINEAR REGRESSION

Unstandardized

Standardized

Standardized

R2

Beta (95% CI)

Beta

P-value

Beta

P-value

R2

EF biplane, %

(LV systolic function)

0.120

Predictors at diagnosis

Male sex

0.026

-2.0 (-5.7, 1,6)

-0.160

0.266

Disease duration, years at FU

0.001

0.02 (-0.12, 0.15)

0.036

0.802

RNP, g/l

0.002

0.0 (-0.004, 0.003)

-0.044

0.765

RF positive

0.015

1.1 (-1.8, 4.1)

0.123

0.438

SLE-like findings

0.021

-2.7 (-8.1, 2.7)

-0.145

0.320

SSc-like findings

0.015

-1.3 (-4.3, 1.7)

-0.123

0.400

PM/DM-like findings

0.120

-3.4 (-6.0, -0.7)

-0.347

0.015

-0.347

0.015

LAS, %

(LV systolic function)

0.299

Predictors at diagnosis

Male sex

0.206

-2.5 (-3.9, -1.19

-0.454

0.001

–0.445

0.002

Disease duration,years at FU

0.010

0.02 (-0.04, 0.08)

0.101

0.484

RNP, g/l

0.000

0.0 (-0.002, 0.001)

–0.020

0.890

RF positive

0.068

1.1 (-0.2, 2.3)

0.261

0.095

SLE-like findings

0.092

-2.4 (-4.7, -0.2)

-0.303

0.035

-0.267

0.055

SSc-like findings

0.018

-0.6 (-1.9, 0.7)

-0.136

0.353

PM/DM-like findings

0.018

-0.6 (-1.8, 0.6)

-0.136

0.351

E’ m/s

(LV diastolic Function)

0.144

Predictors at diagnosis

Male sex

0.009

-0.4 (-1.8, 0.9)

-0.094

0.518

Disease duration, years at FU

0.174

-0.07(-0.11, -0.03)

-0.417

0.003

-0.380

0.008

RNP, g/l

0.091

-0.001 (-0.002, 0.000)

-0.302

0.037

RF positive

0.001

0.1(-1.0, 1.1)

0.022

0.888

SLE-like findings

0.002

-0.3 (-2.2, 1.7)

-0.039

0.791

SSc-like findings

0.074

1.0 (-0.4, 2.1)

0.272

0.058

PM/DM-like findings

0.071

-0.9 (-1.9, 0.1)

-0.266

0.065

Covariates chosen for multivariable linear regression were variables with P ≤ 0.20 in univariable regression and without multicollinearity in the multivariate models. Backward regression based on all potential predictors was performed as sensitivity analysis. P-value for inclusion was 0.05. Variables were removed by backward regression (P=0.10).


Disclosure: B. N. Witczak, None; S. O. Hetlevik, None; Z. Barth, None; T. Schwartz, None; B. Flatø, None; V. Lilleby, None; I. Sjaastad, None.

To cite this abstract in AMA style:

Witczak BN, Hetlevik SO, Barth Z, Schwartz T, Flatø B, Lilleby V, Sjaastad I. Impaired Cardiac Function in Juvenile Mixed Connective Tissue Disease Compared with Controls [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/impaired-cardiac-function-in-juvenile-mixed-connective-tissue-disease-compared-with-controls/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impaired-cardiac-function-in-juvenile-mixed-connective-tissue-disease-compared-with-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology